<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00198991</url>
  </required_header>
  <id_info>
    <org_study_id>GMALL01</org_study_id>
    <nct_id>NCT00198991</nct_id>
  </id_info>
  <brief_title>German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)</brief_title>
  <official_title>German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Krebshilfe e.V., Bonn (Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <brief_summary>
    <textblock>
      The study evaluates the efficacy and tolerability of an intensified induction and
      consolidation therapy. Thereafter patients receive individualised treatment stratified
      according to relapse risk with stem cell transplantation for patients with high and very high
      risk of relapse. Patients with standard risk receive further consolidation and reinduction
      chemotherapy. In parallel minimal residual disease (MRD) is evaluated. After six months and
      one year the decision on intensification or discontinuation of therapy is made based on the
      results of MRD evaluation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2003</start_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission rate, Remission duration, Disease free survival,Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time and dose compliance, Realisation of SCT, Toxicity according to WHO, Course of MRD</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">1250</enrollment>
  <condition>Adult Acute Lymphocytic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asparaginase</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vindesine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VP16</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thioguanine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VM26</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CNS irradiation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mediastinal Irradiation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute lymphoblastic leukemia (pro-B, common, pre-B, early T, thymic T, mature T)

          -  Age 15-65 yrs (*55-65 years if biologically younger according to general condition)

          -  Written informed consent

        Exclusion Criteria:

          -  Severe comorbidity or leukemia associated complications

          -  Late relapse of pediatric ALL or ALL as second malignancy

          -  Cytostatic pre-treatment

          -  Pregnancy

          -  Severe psychiatric illness or other circumstances which may compromise cooperation of
             the patient

          -  Participation in other clinical trials interfering with the study therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Hoelzer, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of Frankfurt, Medical Dept. II</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dieter Hoelzer, MD, PhD</last_name>
    <phone>++49 (0)69 6301 5194</phone>
    <email>hoelzer@em.uni-frankfurt.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicola Goekbuget, MD</last_name>
    <phone>++49(0)69 6301 6365</phone>
    <email>goekbuget@em.uni-frankfurt.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Frankfurt, Medical Dept. II</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dieter Hoelzer, MD,PhD</last_name>
      <phone>++49(0)69 6301 5194</phone>
      <email>hoelzer@em.uni-frankfurt.de</email>
    </contact>
    <contact_backup>
      <last_name>Nicola Goekbuget, MD</last_name>
      <phone>++49(0)69 6301 6365</phone>
      <email>goekbuget@em.uni-frankfurt.de</email>
    </contact_backup>
    <investigator>
      <last_name>Dieter Hoelzer, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicola Goekbuget, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.leukemia-trials.eu</url>
    <description>European Leukemia Trial Registry</description>
  </link>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>May 29, 2008</last_update_submitted>
  <last_update_submitted_qc>May 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2008</last_update_posted>
  <keyword>ALL</keyword>
  <keyword>Treatment</keyword>
  <keyword>de novo</keyword>
  <keyword>Minimal residual disease</keyword>
  <keyword>Adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Cladribine</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
    <mesh_term>Vindesine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

